Stockreport

Clovis Oncology’s Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer

Clovis Oncology, Inc.  (CLVS) 
Last clovis oncology, inc. earnings: 2/24 04:05 pm Check Earnings Report
PDF - Clovis seeks U.S. approval for rucaparib as monotherapy treatment for patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer- FDA submis [Read more]